What a grading framework is for
Reading a paper and forming an impression is fast and unreliable. The impression is shaped by how confidently the abstract is written, whether the result agrees with what you expected, and how recently you read something similar.
A framework replaces that with a set of questions asked in the same way every time: what design, how large, what population, replicated or not, peer-reviewed or not, what conflicts. The score matters less than the fact that each dimension was considered separately.
The dimensions and why each one is there
Study design is weighted most heavily because it determines what conclusions the data can support at all. Randomisation is what allows a difference between groups to be attributed to the treatment; without it, the groups may have differed at the start in ways nobody measured.
Sample size determines whether an effect can be detected reliably. Human versus animal determines whether the result is about people. Replication determines whether the finding survives being tested by someone else, which is the check that catches most false positives.
- •Study design: what the data can support
- •Sample size: whether the effect could be detected reliably
- •Human or animal: whether the result is about people
- •Peer review: whether anyone independent examined the methods
- •Replication: whether it survives independent testing
- •Conflicts of interest: whether the analysis had a preferred answer
- •Regulatory status: whether a regulator has reviewed the dossier
Where informal assessment goes wrong
A single striking result from a small unreplicated study is the most common overweighting. Small studies produce large effect estimates by chance more often than large ones do, and the striking ones are the ones that get published and shared.
The mirror error is dismissing consistent preclinical evidence because it is not human. A coherent mechanism demonstrated across several animal models is a real finding about biology. It is not a claim about clinical outcomes, and both halves of that sentence matter.
What a score cannot capture
Grading assesses the strength of the evidence, not the size of the effect. A very well-evidenced tiny effect scores highly and may still be irrelevant in practice. Effect size and evidence quality are independent axes.
Nor does it capture safety, which is a separate literature with its own quality problems, or whether a result generalises beyond the population studied.
How the evidence grade is calculated
Each dimension is scored on its own scale and combined into a weighted composite, with study design carrying the most weight because it constrains everything downstream.
score = SUM( dimension score x dimension weight ) / SUM( weights )
dimensions: design, sample size, human data, peer review,
replication, conflicts of interest, regulatory status- Score the study design. From meta-analysis at the top through randomised trials, observational studies, case reports, animal work and cell work, to anecdote at the bottom. This is the highest-weighted dimension.
- Score the sample size. Larger studies detect effects more reliably and produce less extreme estimates. A very small study can be right and cannot be relied on alone.
- Score the population. Human clinical data supports a human claim. Animal data supports a hypothesis, and the score reflects the difference rather than eliding it.
- Score process and independence. Peer review, replication and declared conflicts, each separately. Replication carries substantial weight, because independent confirmation is the check that catches most false positives.
- Combine into a weighted composite. The dimensions are weighted rather than averaged equally, so a strong design is not offset by a missing regulatory approval.
What this method cannot tell you
- •It grades evidence quality, not effect size. A well-evidenced trivial effect scores well.
- •The weights are a defensible choice and not the only one. Different frameworks weight these dimensions differently.
- •It assesses one body of evidence for one claim. It does not weigh benefit against risk.
- •It depends on your inputs being accurate. Scoring a study's design generously produces a generous grade.
Where the numbers come from
Evidence grade calculator: frequently asked questions
A widely used framework for rating the certainty of evidence and the strength of recommendations, developed by an international working group and used by many guideline bodies.
This calculator is GRADE-inspired: it borrows the idea of assessing evidence across explicit dimensions rather than reproducing the full formal methodology.
Sources: GRADE working group handbook
Because it determines what the data can support at all. No sample size rescues a design that cannot distinguish the treatment from the way the groups differed at the start.
Because it balances known and unknown confounders between groups. Without it, a difference in outcome may reflect a difference in who ended up in which group.
It is the single feature that most separates a study whose result can be attributed to the treatment from one whose result cannot.
It depends on the effect size being sought. A large effect is detectable in dozens of participants; a small one may need thousands.
A study that reports no effect without a power calculation may simply have been too small to find one.
Because independent confirmation is the check that catches false positives, and false positives are common in single studies.
A finding replicated by three independent groups is in a different category from one reported once, whatever the individual study quality.
No. It is a filter, not a guarantee, and plenty of flawed work passes it.
Its absence is more informative than its presence: a preprint has not been examined by anyone independent at all.
Enough to notice, not enough to dismiss. Industry funding is associated with more favourable results on average, which is a reason for closer reading rather than automatic rejection.
Most clinical trials are funded by the companies developing the treatment, because nobody else has the resources. Declared conflicts are handled better than undeclared ones.
For the approved indication, yes. Approval requires a clinical dossier that a regulator has reviewed.
It says nothing about other uses. Approval is indication-specific and the evidence behind it is too.
Absolutely. The grade describes how confident the evidence justifies being, not whether the claim is correct.
Many well-established findings started as low-graded observations. The grade is a statement about the current state of evidence.
Score the design as animal or in vitro and the human data dimension as none. The composite will be low, which correctly reflects that no human evidence exists.
A low score here is not a criticism of the preclinical work. It is a statement about what has and has not been shown in people.
The tendency for positive results to be published and null results not to be, which makes the published literature systematically more favourable than the total evidence.
It is one reason systematic reviews rank above individual studies: a good review searches for unpublished work and tests for the bias.
A statistical combination of results from multiple studies addressing the same question, producing a pooled estimate with greater precision than any single study.
Its quality depends on the studies going in. A meta-analysis of weak studies is a precise estimate of a biased result.
No, deliberately. Evidence quality and effect size are independent, and a well-evidenced tiny effect deserves a high grade and little practical attention.
As a record of how you reached a judgement, not as the judgement itself. The value is in having considered each dimension separately.
A score with the reasoning attached can be disagreed with specifically, which an impression cannot.
Because they weight the dimensions differently and define the categories differently. There is no single correct weighting.
What matters is that the weighting is explicit, so a disagreement can be located rather than remaining a difference of feeling.
No. It structures an assessment of studies you have read. Scoring a paper from its abstract grades the abstract.
Related Products
Related Research News
What the Human Evidence Actually Shows: A Peptide Evidence Map
Thymosin beta-4 has been through a Phase 3 trial. It was an eye drop, in a corneal disease, and it missed. A five-tier map of where each peptide's evidence actually sits, and why a registered trial that never published is weaker than no trial at all.
Retatrutide Buy Online: Research Evidence and Limits
Retatrutide is a tri-agonist peptide under investigation, but no peer-reviewed study confirms over-the-counter availability. This article clarifies what evidence supports and what remains unproven.
Tesamorelin vs Ipamorelin: Human Evidence, Doses, Safety
Tesamorelin holds FDA approval for HIV-associated lipodystrophy; ipamorelin has none. This page maps the published human dosing data for each and marks the gaps.